← All trials
NCT04943211
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2021
- Primary completion
- Mar 30, 2026
- Completion date
- Jun 23, 2026
- First posted
- Jun 29, 2021
- Last posted
- Jun 29, 2021
- Enrollment
- 150
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Institution of Mother and Child, Warsaw, PolandLead sponsor
- Institution of Mother and Child, Warsaw, PolandOverall official - principal investigator
- Curie InstituteCollaborator
- Institution of Mother and Child, Warsaw, PolandSponsor investigator
- Wrocław University of Environmental and Life SciencesCollaborator
- Łukasiewicz Research NetworkCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.